Value-based contracts (VBC) are increasingly considered by companies for many types of therapies, with some suggesting that VBC will become the default for them across their portfolio. This webinar will explore the sustainability of this approach, what payers and national HTA bodies really want from negotiations and the future of innovative contracting.
Speakers:
Josie Godfrey: Former Associate Director for Highly Specialised Technologies, NICE
Josie’s market access experience covers the establishment of NICE’s Highly Specialised Technologies and Advisory Group for National Specialised Services programmes, including a process for agreeing Managed Access Agreements for very rare diseases. Josie leads Duchenne UK’s Project HERCULES and co-chairs EUCOPE’s CGT Working Group.
Malcolm Qualie: Former Medicines Lead for Specialised Services, NHS England
Malcolm recently retired from his role as NHS England’s Medicines Lead for Specialised Services, where he worked with companies on commercial agreements and service development. Malcolm has been a member of the National Pharmaceutical Supply Group, the national HIV HRG reference group, and the NICE Commissioner reference panel for NICE Guidelines.
Heather McDonald: Global VP, Market Access – Cell and Gene Therapies + Digital Health, Bayer Pharmaceuticals
Heather’s team works with healthcare systems worldwide to ensure that patients have access to Bayer’s innovative products. Heather’s mandate includes Market Access Strategy, Pricing, HEOR and Public Affairs. Previously, Heather was the Vice President of Market Access and Government Affairs for Bayer Canada.